GSK answers Pfizer's RSV approval with data targeting matching nod in younger adults

Preliminary results from two trials showed that GSK’s respiratory syncytial virus (RSV) vaccine Arexvy has potential in younger adults with certain risk factors, potentially positioning the shot for a larger population.